🔗 Share this article

As the US continues making historic changes to its vaccine schedules, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines in the pandemic and has zeroed in on potential fatalities following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Health officials were set to unveil radical changes to the pediatric vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with many the world with no evidence for public health gain. The planned update has been delayed until the next year.

Instead of Vinay Prasad, Høeg is set to present at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to run the office this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants roughly the size of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious track record in medication creation, approval processes or administrative roles, which has been customary for past heads of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who headed CBER have had.”

This division has an enormous portfolio at the FDA, Woodcock pointed out.

“Many people just pays attention on the innovative therapies, but the generic program clears thousands of generic drugs. There is also a biosimilars program, over-the-counter program and more, and every single one must be managed,” Dr. Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management component to the job, which oversees over 5,000 employees. “It is a enormous management job, if you do it right,” Woodcock said.

Response and Contentious Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment represents increased cooperation among agency officials on vaccines, a press secretary said that the “concerns are based on inaccurate presumptions”.

“This background matches the functions of her position,” the representative explained, citing the time Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the agency head's recently launched priority voucher program, a controversial rapid drug-approval program that apparently worried her predecessors. “How are these medications being selected for this fast-track system? Who is making the calls?” Howard said. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he said, “the agency looks to be trending towards laxer rules of all drugs, aside from shots.”

Established Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if concerning, track record, Howard said. She published a analysis using unverified volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are riskier than they are.

Part of her “policy goals” for the new administration encompassed revising guidelines for recently developed shots and ending “non-essential” immunizations, she remarked post-election on a online show. At the agency, Dr. Høeg has allegedly proposed excluding teenage boys from getting COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her beliefs and works backwards to retrofit the evidence in a extremely deceptive, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|